We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phoqus | LSE:PQS | London | Ordinary Share | GB00B0M4CD64 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:0308E
Phoqus Group plc
18 September 2007
Result of EGM - Change of Company Name
West Malling, UK, 18September 2007: Phoqus Group plc (AIM: PQS) ("Phoqus
Pharmaceuticals" or "Company"), the specialty pharmaceuticals drug development
company, announces that the extraordinary general meeting of the Company held
today passed the special resolution to change the Company's name from Phoqus
Group plc to Phoqus Pharmaceuticals plc.
Enquiries:
Phoqus Group plc Tel: 01732 870227
Dr Richard Mason, CEO
Dr Peter Johnson, CFO
Financial Dynamics Tel: 020 7831 3113
David Yates/John Gilbert
Nomura Code Securities Limited Tel: 020 7776 1200
Phil Walker
Notes to Editors
About Phoqus Pharmaceuticals
Phoqus Pharmaceuticals is a speciality pharmaceutical drug development company
developing secondary care products for patients with significant unmet medical
needs through the use of its proprietary drug delivery and re-formulation
technologies. These allow the company to change the pharmacokinetic profile of
drugs, either improving their therapeutic effect (efficacy and/or safety) in
existing indications, or to change their therapeutic effect so that they may
find use in new indications.
Phoqus Pharmaceuticals' core capability is in oral drug delivery and it has
combined its technology platform with expertise in formulating tablets and
tablet coat powders to create a range of innovative and diverse drug delivery
applications. The Phoqus Pharmaceuticals technology is protected by a
substantial patent portfolio. Phoqus Pharmaceuticals' underlying technology
platform is based upon electrostatic dry powder deposition. This process
deposits charged powder particles on to the surface of a substrate with high
precision.
Based in Kent, Phoqus Pharmaceuticals was established in 1998 and was admitted
to trading on AIM in November 2005. It is listed under the symbol "PQS".
Further background on the Company can be found at www.phoqus.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
EGMEAANPFENXEFE
1 Year Phoqus Chart |
1 Month Phoqus Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
